Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
ZacksEdwards Lifesciences’ (EW) TMTT segment’s PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.